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Abstract
There are no effective interventions that significantly forestall or reverse neurodegeneration and
cognitive decline in Alzheimer's disease. In the past decade, the generation of new neurons has been
recognized to continue throughout adult life in the brain's neurogenic zones. A major challenge has
been to find ways to harness the potential of the brain's own neural stem cells to repair or replace
injured and dying neurons. The administration of hematopoietic growth factors or cytokines has
been shown to promote brain repair by a number of mechanisms, including increased neurogenesis,
anti-apoptosis and increased mobilization of bone marrow-derived microglia into brain. In this light,
cytokine treatments may provide a new therapeutic approach for many brain disorders, including
neurodegenerative diseases like Alzheimer's disease. In addition, neuronal hematopoietic growth
factor receptors provide novel targets for the discovery of peptide-mimetic drugs that can forestall
or reverse the pathological progression of Alzheimer's disease.
Hematopoietic growth factors influence 
neurogenesis
Hematopoietic growth factors (HGFs) enhance prolifera-
tion, differentiation, and release of blood cell lineages
into the circulation. Interestingly, these same cytokines
have been shown to influence the proliferation of neural
stem/progenitor cells. Review of the similarities and dif-
ferences between the stem cells that give rise to neural cell
lineages ('neuropoiesis'), and those that generate the var-
ious blood cell lineages (hematopoiesis), has led to the
concept of the 'brain marrow' [1,2]. 'Brain marrow' was
conceived as a proliferative central core of the central
nervous system comprising the subependymal zone and
other cell groups (sub-granular zone of the hippocampal
dentate gyrus) that give rise to new neural cells through-
out life. In addition to requiring special extracellular
matrix and supportive cells (the stem cell 'niches'), both
sets of stem cells require trophic factors, cytokines, and
other molecules that are instructive for proliferation,
migration, and differentiation into their respective cell
lineages. A major overlap between bone and brain mar-
row is seen in the collection of cytokines and trophic fac-
tors that promote blood cell and neural cell development.
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Many of the cytokines and growth factors required for
both hematopoeisis and neuropoiesis are constitutively
expressed by bone marrow (BM) stromal cells [1,2]. Two
cytokine superfamilies produced by BM stromal cells are
transforming growth factor-β and the hematopoietins.
They mediate a range of developmental events in the nerv-
ous system that rivals that of the classic neurotrophins.
The bone morphogenetic proteins (BMPs), a sub-class of
the transforming growth factor-β superfamily, are well
known for their significant effects on the development of
osteocytes and chondrocytes in bone. However, BMP lig-
ands and their receptor subunits are also present through-
out neural development within discrete regions of the
embryonic brain and within neural crest-derived migra-
tory zones [3,4]. BMPs exhibit a broad range of cellular
and context-specific effects during multiple stages of neu-
ral development [5]. For example, BMPs initially inhibit
the formation of neuroectoderm during gastrulation,
while within the neural tube they act as gradient morpho-
gens to promote the differentiation of dorsal and interme-
diate cell types through co-operative signaling. BMP-2 acts
synergistically with fibroblast growth factor (FGF2) on
more lineage-restricted embryonic central nervous system
progenitor cells to induce the expression of the dopamine
neuronal marker tyrosine hydroxylase [6]. Various hemat-
opoietic cytokines have been shown to enhance the
number of dopaminergic neurons in mesencephalic cul-
tures, but only interleukin-1 induced the expression of the
dopamine neuronal marker tyrosine hydroxylase in the
progenitor cells [7].
Other regulatory proteins that influence blood cell differ-
entiation have effects on neuronal development. Erythro-
poietin, in addition to its function to promote the
production of red blood cells, also has trophic effects on
central cholinergic and cortical neurons [8]. Erythropoie-
tin receptor mRNA is expressed in the mouse brain and in
the central nervous system of the developing human fetus.
Neuronal cell lines, including PC12 and SN6, also express
a functional erythropoietin receptor. The neurotrophic
activity of erythropoietin has been demonstrated in neu-
ral cells [9]. A 17-mer peptide sequence (EPO peptide) in
erythropoietin has been identified that has activity similar
to that of the holoprotein [9]. This peptide induced differ-
entiation and prevented the proliferation of erythropoe-
itic cell lines and mouse primary spleen cells. When the
EPO peptide or erythropoietin was locally injected into
mice, the frequency of motor end plate sprouting in adja-
cent muscles increased in a manner similar to that
induced by ciliary neurotrophic factor. Since neural cells,
but not hematological cells, respond to a specific peptide
sequence within erythropoietin, it is likely that the holo-
protein has separate domains for neurotrophic and hema-
totrophic functions.
Neural stem/progenitor cells of the brain express c-kit, the
receptor for one of the major hematopoietic cytokines,
stem cell factor (SCF). In hematopoietic cells, SCF and c-
kit regulate a variety of developmental events, including
cell proliferation, survival and differentiation [10]. SCF
has also been shown to stimulate neurogenesis both in
vitro and in vivo [11]. Not only is c-kit expressed in neuro-
genic zones of the brain, but ischemia has been reported
to alter c-kit expression, which in turn stimulates neural
stem cell (NSC) proliferation and differentiation into
neurons [11]. The interaction of SCF with its receptor c-kit
on NSCs also appears to play a key role in triggering NSC
migration from the neurogenic zones to sites of brain
injury [12].
Granulocyte-colony stimulating factor (G-CSF) is a potent
growth factor that stimulates proliferation of hematopoi-
etic stem cells and drives differentiation of myeloid line-
age cells. It is used extensively in clinical practice to
accelerate recovery of patients from neutropenia after
cytotoxic therapy. G-CSF also impacts neural tissues [13].
When administered systemically, it crosses the blood-
brain barrier [14]. The G-CSF receptor and its ligand are
expressed by neurons in a variety of brain regions, includ-
ing pyramidal cells in cortical layers (particularly in layers
II and V), Purkinje cells in the cerebellum, the subven-
tricular zone and in cerebellar nuclei in rats [14]. G-CSF
positive cells have been identified in the CA3 region of the
hippocampus, the subgranular zone and hilus of the den-
tate gyrus, entorhinal cortex, and the olfactory bulb [14].
G-CSF receptor expression has also been shown in the
frontal cortex of human brain by postmortem studies
[14].
Both neuronal G-CSF and its receptor are up-regulated in
the ipsilateral forebrain hemisphere 2 hours after the
occlusion of the middle cerebral artery and reperfusion in
a rat model of stroke [14]. In a similar study, G-CSF
mRNA levels were massively increased by ischemia com-
pared to normal cortex and returned to control levels after
2 days [15]. The increase in G-CSF mRNA expression
extended beyond the ischemic lesions to include non-
ischemic frontal cortex after photothrombosis in a rat
model of focal cerebral ischemia [15]. In a mouse model
of stroke, administration of the combination of G-CSF
and SCF 10 days after ischemia effectively improved
motor performance, induced transition of BM-derived
neuronal cells into the peri-infarct area, and stimulated
proliferation of intrinsic neural stem/progenitor cells in
the neuroproliferative zone [16]. It has been suggested
that G-CSF may have a protective autocrine signaling
mechanism in response to neural injury, similar to a
mechanism suggested for other growth factors, especially
erythropoietin [17].BMC Neuroscience 2008, 9(Suppl 2):S3 http://www.biomedcentral.com/1471-2202/9/S2/S3
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Bone marrow-derived cells in Alzheimer's 
disease
A growing focus of research has been on the discovery of
multipotent stem cells in BM that are capable of giving
rise to tissues of all embryonic germ layers [18]. BM-
derived cells have been shown by independent investiga-
tors to give rise to neural cells and these may migrate to
brain where they appear to differentiate into neurons and
glia [19-22]. The mechanism for transdifferentiation of
BM to neural cells is not clear and may reflect the capacity
of BM-derived cells to fuse with injured neurons [23].
The demonstration of transdifferentiation of BM cells has
primarily been performed in vitro, utilizing different sub-
populations of marrow, and various combinations of cell
culture media and growth factors. The combination of
retinoic acid and brain-derived neurotrophic factor
(BDNF) was effective in driving a BM stromal cell popula-
tion into neuron-like cells [19]. More recently, other
researchers have reported that a fragment of amyloid pre-
cursor protein potentiates the nerve growth factor/retinoic
acid-induced transdifferentiation of BM-derived adult
progenitor cells into neural progenitor cells and, more
specifically, enhances their terminal differentiation into a
cholinergic-like neuronal phenotype [24]. In vivo work on
the problem of transdifferentiaton suggests that genera-
tion of new neurons from a bone marrow progenitor, if it
really occurs, may be a rare phenomenon. Nevertheless,
BM cells from the periphery are the source of a small pro-
portion of the brain's immune cells (microglia) in the
normal adult brain, and following various brain injuries,
the trafficking of BM cells from blood to brain is markedly
increased.
Microglia have been clearly observed in the core of amy-
loid plaques in transgenic mouse models of Alzheimer's
disease (AD). Perhaps as many as 10% of these cells orig-
inate from the BM, and the amyloid-β (Aβ)-40 and Aβ-42
isoforms are able to trigger this chemoattraction. These
newly recruited cells also exhibit a specific immune reac-
tion to both exogenous and endogenous Aβ in the brain
[25].
Infiltration of the brain parenchyma by BM-derived cells
in the course of cerebral amyloidosis has been demon-
strated by tracking green fluorescent protein (GFP)-BM in
the tg mouse model (APP23 mice) of AD [26]. These mice
underwent lethal irradiation and were rescued by BM
replacement with GFP-expressing BM cells (from a tg GFP
mouse line). Interestingly, aging amyloid-depositing
APP23 mice exhibited a significant increase in the number
of invading GFP-positive cells compared with age-
matched, non-transgenic control mice. Only a subpopula-
tion of amyloid deposits was surrounded by invading
cells, suggesting that not all amyloid plaques were a target
for invading cells. Another possibility was that all amyloid
plaques attracted infiltrating immune cells, but only for a
limited time, possibly at an early stage of plaque evolu-
tion. Immunological and ultra-structural phenotyping
revealed that macrophages and T cells accounted for a sig-
nificant portion of these ameboid-like invading cells.
Macrophages did not show evidence of amyloid phagocy-
tosis at the electron microscopic level, and no obvious
signs of T cell-mediated inflammation or neurodegenera-
tion were observed. Hence, the observation that BM-
derived cells invade the brain in response to cerebral amy-
loidosis may provide a novel therapeutic approach [26].
In another study, young transgenic mice were trans-
planted with GFP+ BM cells to create chimeric mice before
the onset of AD-like pathology and their brains were ana-
lyzed 6.5 months later. The number of engrafted BM-
derived cells was significantly higher than in age-matched
wild-type mice. Moreover, the number of BM-derived cells
associated with Aβ was significantly higher than in older
transgenic mice transplanted after the establishment of
AD-like pathology. Local inflammation caused by intra-
hippocampal lipopolysaccharide injection significantly
increased the engraftment of BM-derived cells in old AD
mice and decreased the hippocampal Aβ burden. These
results suggest that infiltration of BM-derived monocytic
cells into the brain contributes to the development of a
microglial reaction in AD [27].
Most recently, administration of G-CSF into two different
Aβ-induced AD mouse models substantially improved
performance on the Morris water maze [28]. In the 'acute'
model of AD, aggregated Aβ was injected into the junction
of the hippocampus and cortex of the C57BL/6 mouse
brains. In the chronic model of AD, the investigators used
Tg2576 mice, which overexpress the human amyloid pre-
cursor protein with the Swedish mutation. The adminis-
tration of G-CSF also resulted in enhanced incorporation
of bromodeoxyuridine by hematopoietic stem cells
(HSCs), as well as local neurogenesis surrounding the Aβ
aggregates. In addition, the level of acetylcholine in the
brains of Tg2576 mice was considerably enhanced upon
G-CSF treatment [28]. However, the five day course of G-
CSF had no effect on brain amyloid load measured either
immunohistochemically or by ELISA. In contrast, a two-
week course of G-CSF administration to a double trans-
genic mouse model of AD (tg APP/PS1) resulted in a sig-
nificant decrease in amyloid burden as well as
improvement in cognitive performance in a radial arm
water maze [29].
G-CSF/G-CSF receptor
A promising target for the development of a novel anti-AD
therapy is the G-CSF receptor and its ligand G-CSF. The
natural human glycoprotein exists in 174 and 180 aminoBMC Neuroscience 2008, 9(Suppl 2):S3 http://www.biomedcentral.com/1471-2202/9/S2/S3
Page 4 of 6
(page number not for citation purposes)
acid forms of approximately 19,600 grams per mole. The
more abundant and active 174 residue form has been
used in the development of pharmaceutical products by
recombinant DNA technology. The three proprietary
recombinant G-CSF proteins include lenograstim (Grano-
cyte®), filgrastim (Neupogen®), and pegylated filgrastim
(Neulasta®); the pegylation conferred a longer duration of
action.
Although G-CSF has been used primarily as an agent to
treat leukopenia, the agent has been studied in animal
models of stroke where it has been reported to reduce
brain damage and improve outcome [30-33]. Several
ongoing clinical trials are evaluating the effectiveness and
safety of G-CSF for treatment of ischemic stroke, the
results of which are still pending [34]. It has also been
used experimentally to treat myocardial infarction in
humans [35-39]. In addition, G-CSF has putative neuro-
protective activities independent of its regulation of gran-
ulocyte differentiation and stem cell mobilization
[31,33].
G-CSF receptor, a member of the hematopoietin cytokine
receptor superfamily, functions as a homodimer and
requires the recruitment of cytosolic protein tyrosine
kinases to transduce its signal [40]. At least two protein
tyrosine kinases are primarily involved: Jak2, a member of
the Janus family, and Lyn, a member of the Src family.
Through poorly understood mechanisms, these kinases
functionally interact with the G-CSF receptor. Jak2 prima-
rily enlists members of the signal transducer and activator
of transcription (STAT) family and Lyn phosphorylates a
number of adaptor molecules linking the G-CSF receptor
to phosphatidylinositol 3'-kinase and the extracellular sig-
nal-regulated kinase (Erk) pathways [40]. The characteri-
zation of the specific intracellular signaling pathways to
distinct cell responses elicited by G-CSF is a major objec-
tive of current studies [40].
Stem cell factor (c-kit ligand)
SCF is a glycoprotein (also known as 'steel factor' or c-kit
ligand) that plays a key role in hematopoiesis, acting both
as a positive and negative regulator, often in synergy with
other cytokines. It also plays a pivotal role in mast cell
development, gametogenesis, melanogenesis and neuro-
genesis. The SCF receptor, c-kit, is expressed in neural pro-
genitors in cell cultures and in neuroproliferative zones of
the adult rat brain. In vivo administration of SCF increased
bromodeoxyuridine labeling of immature neurons in
these regions [11]. When SCF was co-administered with
G-CSF 10 days after an ischemic lesion in the mouse, the
recovery of function and enhancement of neurogenesis
was much greater than when either was given alone [16].
Translation to clinical trials in Alzheimer's 
disease
Since G-CSF is already in advanced clinical trials for
ischemic stroke [34], pre-clinical research with this HGF
should be easily translated into therapeutic trials for AD.
The initial approach would be to mobilize the patient's
BM by administering drugs (HGFs such as G-CSF and/or
SCF) that increase the infiltration of BM-derived cells into
the brain where they can effectively reduce the amyloid
load and promote other repair processes, including the
formation of new neurons. Another approach would uti-
lize the BM transplantation paradigm. AD patients would
have an infusion of BM that is genetically engineered to
deliver critical proteins that might enhance clearance of
amyloid, provide neuroprotection, and stimulate neuro-
genesis. Eventually, a drug discovery screening program
designed to target the G-CSF receptor should be able to
find peptide-mimetics that interact with the G-CSF-recep-
tor to produce the desired biological effects.
Conclusion
The application of HGF for the treatment of AD has not
yet been undertaken but there is a strong rationale for ini-
tiating clinical studies. In the past five years it has become
evident that BM houses more 'primitive', multipotent
stem cells that are capable of giving rise to tissues of all
embryonic germ layers. BM-derived cells have been
shown by independent investigators to give rise to neural
cells in vitro, and in vivo studies have shown that BM cells
migrate into the brain where they appear to differentiate
into neurons and glia. The mechanism for transdifferenti-
ation of BM to neural cells is not clear and may reflect the
capacity of BM-derived cells to fuse with injured neurons.
The in vitro demonstrations of transdifferentiation of BM
cells has utilized different sub-populations of marrow and
various combinations of cell culture media and growth
factors. The combination of retinoic acid and BDNF were
effective in driving a stromal BM cell population into neu-
ron-like cells. More recently, a fragment of amyloid pre-
cursor protein has been reported to potentiate the nerve
growth factor/retinoic acid-induced transdifferentiation
of BM-derived adult progenitor cells into neural progeni-
tor cells, and more specifically, enhances their terminal
differentiation into a cholinergic-like neuronal pheno-
type. In vivo studies on the problem of transdifferentiation
suggest that generation of new neurons from a bone mar-
row progenitor, if it really occurs, may be a rare phenom-
enon. Nevertheless, BM cells from the periphery are the
source of at least 10% of the adult brain's immune cells
(microglia) under normal conditions, and following vari-
ous brain injuries, the trafficking of BM cells from blood
to brain is markedly increased. Microglia have been
clearly observed in the core of amyloid plaques in trans-
genic mouse models of AD. Perhaps as many as 10% of
these cells originate from the BM and the Aβ-40 and Aβ-BMC Neuroscience 2008, 9(Suppl 2):S3 http://www.biomedcentral.com/1471-2202/9/S2/S3
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42 isoforms are able to trigger this chemoattraction. These
newly recruited cells also exhibit a specific immune reac-
tion to both exogenous and endogenous Aβ in the brain.
G-CSF inhibits programmed cell death and promotes neu-
rogenesis. Given that G-CSF administration in a mouse
model of AD has been reported to improve performance
in a hippocampal-dependent learning task and adminis-
tration of G-CSF has been shown to be safe and well-tol-
erated in early clinical studies in patients with ischemic
stroke, initiation of clinical trials to reverse dementia or
forestall progression of AD is warranted.
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